This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Cell & Gene Therapy Manufacturing & Commercialization US

Early Registration Savings Deadline Expires In

  • 00
  • 00
  • 00
  • 00
Delivered as a Hybrid Event
September 27-30, 2022Boston Convention and Exhibition Center

Kumar Dhanasekharan
Senior Vice President of Technical Operations at Renovacor


Dr. Kumar Dhanasekharan is SVP of Technical Operations at Renovacor Inc. and has over 20 years’ experience in biologics development and manufacturing and most recently, in AAV gene therapy process and analytical development and manufacturing in the last few years. He has worked on several protein therapeutics and AAV gene therapy programs that were successfully taken into the clinic, including process and analytical development and Phase I/II manufacturing of multiple AAV gene therapy programs. He has worked at small and large companies such as Swanbio, Amicus and Genzyme-Sanofi, and also at Catalent (CDMO) leading to successful INDs, PPQs, new facility designs and approvals. Kumar has a Ph.D. in Food Science from Rutgers University with focus on engineering and manufacturing and a Bachelor's in Chemical Engineering from Indian Institute of Technology, Chennai, India. He has over 50 conference presentations and many peer-reviewed publications.

Agenda Sessions

  • Plenary Panel Discussion: Rapid Expansion in the CGT Field - Manufacturing Capacity to Meet Demand

  • Panel Discussion: Relationship Management - Best Practises for Working with CDMO and Suppliers